Delving into the Latest Updates on Strontium Ranelate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Bivalos, Osseor, Ossum

+ [13]

Target

CaSR

Action

agonists

Mechanism

CaSR agonists(Calcium sensing receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases

Active Indication

Osteoporosis, Postmenopausal

Inactive Indication-

Originator Organization

Les Laboratoires Servier SAS

Active Organization

Institut de Recherches Internationales Servier

Inactive Organization

Les Laboratoires Servier SAS

License Organization

Astellas Pharma, Inc.

Les Laboratoires Servier SASAdir et CIE

+ [1]

Drug Highest PhasePhase 3

First Approval Date

European Union (20 Sep 2004),

Osteoporosis, PostmenopausalOsteoporosis

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H10N2O8SSr2

InChIKeyWJKLKWHUBHCSFS-UHFFFAOYSA-N

CAS Registry135459-87-9

This study is being conducted with the aim of comparing the time to bone healing after surgery for fragility fractures of proximal femur between patients receiving strontium ranelate and placebo. Patients recruited are of 60 years of age and above. Bone healing will be assessed on clinical parameters when patient is able to ambulate full weight bearing without pain and on Xray images using RUSH score. Moreover Dexa scan will be performed pre-operatively and at 3 months postoperatively. The findings of this study will help in setting up guidelines for treatment of fragility proximal femur fractures in our population as there is still paucity of literature on effectiveness of strontium ranelate from our part of the world.

Start Date01 Nov 2021

Sponsor / Collaborator

AGA Khan University Hospital

NCT03937518

/ CompletedNot ApplicableIIT

Strontium Ranelate as New Modality in Treatment of Primary Knee Osteoarthritis

The present study was carried out on thirty patients with primary knee osteoarthritis. Patients were recruited from Rheumatology and Rehabilitation
Outpatient Clinic at Mansoura University Hospi Patients were divided into two groups:
Group 1: included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years, they were 11 females and 4 males. Group 2: included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years, they were 12 females and 3 males. Written consent was obtained from each participant sharing in the study. This study was approved by the institution research board of faculty of medicine, Mansoura University, code: MS/15.10.08. Inclusion

Start Date01 Jul 2018

Sponsor / Collaborator

Mansoura University

EUCTR2011-000708-17-AT

/ TerminatedPhase 3

A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with bisphosphonates

Start Date27 Aug 2013

Sponsor / Collaborator

Institut de Recherches Internationales Servier

100 Clinical Results associated with Strontium Ranelate

Login to view more data

100 Translational Medicine associated with Strontium Ranelate

Login to view more data

100 Patents (Medical) associated with Strontium Ranelate

Login to view more data

833

Literatures (Medical) associated with Strontium Ranelate

01 Mar 2026·BONE

Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS)

Review

Author: Naciu, Anda Mihaela ; Winter, Elizabeth M ; Anastasilakis, Athanasios D ; Makras, Polyzois ; Papapoulos, Socrates E ; Rolvien, Tim ; Appelman-Dijkstra, Natasha M ; Paccou, Julien ; Lems, Willem F ; Yavropoulou, Maria P ; Carey, John J

PURPOSE:

This narrative review explores the therapeutic potential of repurposing medications originally developed or approved for osteoporosis to treat non-osteoporotic conditions. Given their pharmacologic profiles and safety data, these agents offer promising therapeutic alternatives in both rare and common diseases with unmet clinical needs.

PRINCIPAL RESULTS:

Evidence from preclinical models, observational data, and randomised trials supports the repositioning of several osteoporosis drugs. Cyclic etidronate has shown efficacy in halting arterial calcification progression in pseudoxanthoma elasticum. Pamidronate has demonstrated symptom improvement in adult chronic nonbacterial osteitis. Neridronate is approved only in Italy for complex regional pain syndrome type I. Denosumab has shown therapeutic effects in Langerhans cell histiocytosis and has structural benefits in erosive hand osteoarthritis and rheumatoid arthritis. Parathyroid hormone analogues (rhPTH [1-84] and teriparatide) improve calcium-phosphate homeostasis in chronic and genetic hypoparathyroidism. Calcilytics, though originally discontinued for osteoporosis, show emerging promise in autosomal dominant hypoparathyroidism. In contrast, zoledronic acid has not demonstrated consistent clinical benefit in knee osteoarthritis. Strontium ranelate, despite showing structure-modifying effects in osteoarthritis, is no longer marketed due to safety concerns. Alendronate and denosumab in fibrous dysplasia yielded mixed results, with concerns about rebound effects after denosumab withdrawal.

CONCLUSIONS:

Repurposing osteoporosis medications represents a cost-effective, timely strategy to expand treatment options across diverse clinical indications. While promising outcomes have been demonstrated-particularly in rare diseases-rigorous, indication-specific clinical trials are essential to confirm efficacy, safety, and long-term outcomes. The accumulated pharmacologic and clinical experience with these agents offers a strong foundation for their continued exploration beyond osteoporosis.

01 Dec 2025·Bioactive Materials

Modulation of bone homeostasis by dual drug-loaded premixed magnesium tri-magnesium phosphate bone cement for the treatment of osteoporotic vertebral compression fractures

Article

Author: Liu, Jiawei ; Goto, Takashi ; Dai, Honglian ; Yang, Shuhui ; Wang, Xiumei ; Zhu, Jinjin ; Kang, Honglei

Osteoporotic vertebral compression fractures (OVCF) have emerged as a significant public health concern. Traditionally, poly(methyl methacrylate) (PMMA) has been utilized in clinical to treat OVCF. Nevertheless, its poor degradability, uncontrollable setting time, high curing temperatures, and the potential for cement leakage have limited their application. In addition, these bone cements required clinical handling, bringing inconvenience to surgery.This study developed a premixed magnesium phosphate bone cement loaded with strontium ranelate and bioglass microspheres grafted with alendronate sodium (pTMPC-SMA), to achieve regulation between osteogenesis and osteoclastogenesis on osteoporosis. The premixed cement offered storage stability, easy of use, anti-washout behavior, and sustained drug release properties. The in vivo osteoporotic rabbit vertebroplasty model demonstrated that pTMPC-SMA exhibited excellent cavity-filling adaptability, significantly enhanced new bone formation, and achieved superior osseointegration compared to the PMMA group. These findings demonstrate that pTMPC-SMA provides both excellent handling properties and osteogenic therapeutic advantages for treating osteoporosis-related bone defects.

01 Oct 2025·Tissue Engineering and Regenerative Medicine

Correction: Construction of Chitosan Oligosaccharide-Coated Nanostructured Lipid Carriers for the Sustained Release of Strontium Ranelate

Author: Kwon, Il Keun ; Yoo, Daehyeon ; Heo, Dong Nyoung ; Lee, Taek ; Min, Sung Jun ; Seo, Yoseph ; Lim, Hayeon

1

News (Medical) associated with Strontium Ranelate

07 Dec 2018

·www.bioportfolio.com

Human medicines European public assessment report (EPAR): Osseor, strontium ranelate, Osteoporosis, Postmenopausal, Date of authorisation: 20/09/2004, Revision: 19, Status: Authorised

This article has expired, however you can still download the PDF. Preview: Human medicines European public assessment report (EPAR): Osseor, strontium ranelate, Osteoporosis, Postmenopausal, Date of authorisation: 20/09/2004, Revision: 19, Status: Authorised...

100 Deals associated with Strontium Ranelate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08468	Strontium Ranelate	M05BX03	DB09267

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Osteoporosis	European Union	Les Laboratoires Servier SAS	20 Sep 2004
Osteoporosis	Iceland	Les Laboratoires Servier SAS	20 Sep 2004
Osteoporosis	Liechtenstein	Les Laboratoires Servier SAS	20 Sep 2004
Osteoporosis	Norway	Les Laboratoires Servier SAS	20 Sep 2004
Osteoporosis, Postmenopausal	European Union	Les Laboratoires Servier SAS	20 Sep 2004
Osteoporosis, Postmenopausal	Iceland	Les Laboratoires Servier SAS	20 Sep 2004
Osteoporosis, Postmenopausal	Liechtenstein	Les Laboratoires Servier SAS	20 Sep 2004
Osteoporosis, Postmenopausal	Norway	Les Laboratoires Servier SAS	20 Sep 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SEKOIA (WCO_IOF_ESCEO2020)	Phase 3	Osteoarthritis, Knee	-	Control arm of the Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA)	fmefwfadaw(sovpjflijj) = huckcytnqr qcduhoqdln (alryjwlzzc, 0.12)	Positive	20 Aug 2020
WCO_IOF_ESCEO2018	Phase 3	Osteoporosis	83	Strontium ranelate 2g	kvcbpzwezy(zffkxzdbsd) = eiuepfxiet szaijwjiae (irypxffnmj, 0.098)	Negative	27 Jul 2018
				Placebo	kvcbpzwezy(zffkxzdbsd) = naeftscdqv szaijwjiae (irypxffnmj, 0.085)
ISRCTN41323372 (Pubmed \| Rheumatology (Oxford))	Phase 3	Osteoarthritis, Knee	-	Strontium ranelate 2 g/day	cumohkdmqf(fxqibqlues) = jpzaxggjuv uwezlbwlhm (dzubzweakb ) View more	-	01 Aug 2014
				Placebo	cumohkdmqf(fxqibqlues) = iqaqgrvkhs uwezlbwlhm (dzubzweakb ) View more
EULAR2014	Not Applicable	Osteoporosis	134	Alfacalcidol	ebwvxabjvp(xcpduyoqgh) = tzopybqaxe akbqvqfaon (aplyyxiwub )	-	11 Jun 2014
				Calcitonin	ckhmnsvalg(befnxizgdv) = usbmblhfon zuvmvgyppz (nphfbgjnqk ) View more
WCO_IOF_ESCEO2014	Not Applicable	Osteoarthritis, Knee	40	Strontium ranelate 2g/day	yftiavnsse(wqmyltnncp) = uinxqxmogv oydoymqkuc (eoxxpvsamn )	Positive	02 Apr 2014
WCO_IOF_ESCEO2014	Phase 3	-	22	Strontium Ranelate 2g/day	jzqhkzvadc(qdbyevdapr) = crvqbovqqz osnfwqcxdq (ijglbbxtkf )	Positive	02 Apr 2014
ACR2013	Phase 3	Fractures, Bone	48	Strontium Ranelate 2g/day	fixfolarhe(tlwghfviro) = dujkzouiar bgmhnprszl (wkswnirczp, 3.6)	Positive	25 Oct 2013
SEKOIA (EULAR2013)	Phase 3	Osteoarthritis, Knee	330	Strontium ranelate 2 g/day	sntmhosalf(vpcurwmoxa): P-Value = 0.001	-	12 Jun 2013
				Placebo
SEKOIA (EULAR2013)	Phase 3	Osteoarthritis, Knee	1,371	Strontium ranelate 2g/day	uxrbjvdtdg(xwrpdncxuw) = uxljjzhjkm prlrigcgng (ugaxzgoddb )	Positive	12 Jun 2013
SEKOIA (ACR2012)	Phase 3	Osteoarthritis, Knee	1,371	Strontium ranelate 2g/day	frlaswshqd(guhmrbpruf) = girlvgmsfv nlcvxdcaic (hggrnpbqag ) View more	Positive	09 Nov 2012
				Placebo	frlaswshqd(guhmrbpruf) = xqchmjgpug nlcvxdcaic (hggrnpbqag ) View more